
Agreement revolves around sustainability, but also features implementation of new bioprocess development methods

Agreement revolves around sustainability, but also features implementation of new bioprocess development methods

Plant will be CDMO’s first standalone GMP and vaccine development manufacturing site in the country

Former Novartis plant will become mRNA manufacturing facility, the first in Singapore

Alliance revolves around interoperability of pharma products as they move through the supply chain

Purchase will help CDMO expand into European market

Manufacturing plant addition features nine new processing suites

New microbial fermentation tech expected to boost CDMO’s overall capacity

Recession warnings impacting the flow of goods and services

Prescription drugs are the main drivers in this effort

Kaysersberg facility’s Lab+ deal expected to bolster CDMO’s filling services

Storage perk will be a mainstay at facility near Frankfurt Airport

The latest people news happenings over the past month

Center, expected in 2023, will support pharma and med device sectors

Non-exclusive deal intends to popularize RTU containment solutions within pharma industry

Center implements Industry 4.0 principles

Deal is valued at $21.9 million

Invests $5 million to upgrade manufacturing processes

Offers more than 120 hours of temperature-controlled pharma product protection

ACC supports both clinical and commercial viral vector production

Expansion project addresses assay development demands

Offers over 100,000 square feet of pharma temperature-controlled storage

Organization’s PAI portfolio boosts drug R&D, process development for pharma manufacturers

Healthcare marketing agency acquisition augments company’s commercialization portfolio

WEF honor is for demonstration of leadership in adopting Industry 4.0 tech

Project is centered around drug substance manufacturing

Expected to improve patient centricity, simplify clinical development process through commercialization

Wholesalers continue to worry about manufacturer commitment to timely compliance

Agreement featuring UK pharma services consultancy intends to grow PharmaLex's pan-European market access presence

P4 is partially operational in under two years